BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed bone-graft device, Augment, wouldn't be approved without more information from previous studies. The company says it plans to submit the necessary information by the middle of the year. Shares -10.7% AH.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs